Navigation Links
Pharmacopeia to Host First Quarter 2008 Financial Results Webcast and Conference Call
Date:4/23/2008

and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including eight clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. For more information please visit the company's website at http://www.pharmacopeia.com.

Contact:

Amy P. Sharpless

Corporate Communications

(609) 452-3643

ir_pr@pcop.com

This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are av
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference
3. Pharmacopeia Announces Management Team Changes
4. Pharmacopeia to Present at the Cowen and Company 28th Annual Health Care Conference
5. Pharmacopeia to Receive $5 Million Payment from GlaxoSmithKline
6. Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference
7. Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
10. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
11. Genmab Announces 2007 First Half Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... and BANGALORE, India , July ... profiling company that uses next generation sequencing technology to ... Scott A. Storrer as chief executive officer. In ... will be responsible for all strategy, business expansion and ... who has served as Strand,s chairman and CEO since ...
(Date:7/1/2015)... July 1, 2015  Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced that the ... 22 at 5:45 p.m. EDT following its presentation ... International Conference 2015 (AAIC). The ... , Dr. Lawrence Friedhoff , Chief Development ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan contest ... the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s Startup Challenge ... of US$15,000 and a period of expert mentorship from a senior industry figure drawn ...
(Date:7/1/2015)... Indianapolis, IN (PRWEB) , ... July 01, 2015 , ... ... the 2015 BIO International Convention in Philadelphia, PA. , The presentation took ... milestones and outlined the plans for the development of APX3330 for the treatment of ...
Breaking Biology Technology:Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2
... gave about $400,000 worth of software to Lad ... and their families. Rob Busch, enterprise sales manager for ... the non-profit's Synergy School in Milwaukee for the formal ... upgrade Lad Lakes network and software infrastructure, including the ...
... NimbleGen Systems Inc. closed its latest, $8.2 ... to $50 million, the company said. , ,The company makes ... have thousands of individual genetic samples on them arranged in ... of DNA and do comparisons. , , Cargill Ventures ...
... in the next ten years, according to a proposal that ... the Senate for a vote this month. State Senator Joe ... Wisconsin that would be regulated similarly to airports. , ,Leibhams ... regulate private space travel in the area, receive any potential ...
Cached Biology Technology:Space port could open in Sheboygan in next 10 years 2Space port could open in Sheboygan in next 10 years 3
(Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., a ... by the United States Patent and Trademark Office (USPTO) ... process leverages TAKE Solutions, Clinical Accelerators to reduce the ... (when compared to standardization without the accelerators), thus reducing ... At the heart of the patented ...
(Date:6/24/2015)... Switzerland , June 24, 2015 ... partnership with emerging biometric password solution one face ... one face in, entering ... a ground-breaking and affordable multifactor-authentication biometric answer to ... recognition technology, provided in partnership with KeyLemon, one ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... Sultans of Soil, they're just clever Lab guys. A team ... week's Science Magazine with a new way to count bugs ... beneath our feet. , "Computational Improvements Reveal Great Bacterial Diversity ... Wolinsky and John Dunbar, of Los Alamos' Bioscience Division, describes ...
... the Dirt Doctors, or Sultans of Soil, they're just clever ... a paper in this week's Science Magazine with a new ... the highly complex world beneath our feet. , "Computational Improvements ... by Jason Gans, Murray Wolinsky and John Dunbar, of Los ...
... that combinations of chemicals found in everyday products and ... fertility. , Professor Lynn Fraser told the 21st annual ... Embryology today (Wednesday), that her previous research had shown ... hormone, oestrogen, could individually affect the correct functioning of ...
Cached Biology News:Comparison of Cocaine, Methamphetamine ‘Highs?Finds Differences 2Using computers and DNA to count bacteria 2Environmental chemical cocktail may sabotage sperm 2Environmental chemical cocktail may sabotage sperm 3
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
Homo sapiens MEP50 protein, mRNA...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Biology Products: